[Gastric aspiration therapy is a possible alternative to treatment of obesity].

Abstract

Aspiration therapy with AspireAssist is a novel endoscopic obesity treatment. Patients aspirate approximately 30% of an ingested meal through a draining system connected to a percutanous endoscopic gastrostomy tube. AspireAssist was recently approved by the US Food and Drug Administration, and it induces weight loss comparable to the weight loss observed after bariatric surgery, but with a lower risk of complications. Few clinical studies about the efficacy and safety of AspireAssist have been carried out and published. Thus, further intervention studies evaluating acute as well as long-term effects are warranted.

• Authors: Marie Møller Christensen, Tina Jorsal, Lars Peter Skat Naver, Tina Vilsbøll, Filip Krag Knop
• Journal: Ugeskrift for laeger (Ugeskr Laeger) Vol. 179 Issue 32 (Aug 07 2017) ISSN: 1603-6824 [Electronic] Denmark
• PMID: 28869025 (Publication Type: Journal Article, Review)

Topics

• Denmark
• Device Approval
• Diabetes Mellitus, Type 2 (therapy)
• Endoscopy, Gastrointestinal (adverse effects, methods)
• Feeding Behavior
• Gastrostomy (adverse effects, methods)
• Humans
• Obesity (therapy)
• Quality of Life
• Suction (adverse effects, methods)
• Weight Loss